CAMKK2 and lung cancer: Simultaneously, CaMKK2 activated downstream AMPK, finally providing anti-anoikis and pro-metastatic signals in LKB1-deficient lung cancer, resulting in a poor prognostic outcome for LKB1-deficient lung cancer patient (Fig. 1).